Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Jan 25;307(4):373-81.
doi: 10.1001/jama.2011.2035.

Lansoprazole for children with poorly controlled asthma: a randomized controlled trial

Writing Committee for the American Lung Association Asthma Clinical Research Centers; Janet T Holbrook, Robert A Wise, Benjamin D Gold, Kathryn Blake, Ellen D Brown, Mario Castro, Allen J Dozor, John J Lima, John G Mastronarde, Marianna M Sockrider, W Gerald Teague
Collaborators
Randomized Controlled Trial

Lansoprazole for children with poorly controlled asthma: a randomized controlled trial

Writing Committee for the American Lung Association Asthma Clinical Research Centers et al. JAMA. .

Abstract

Context: Asymptomatic gastroesophageal reflux (GER) is prevalent in children with asthma. Untreated GER has been postulated to be a cause of inadequate asthma control in children despite inhaled corticosteroid treatment, but it is not known whether treatment with proton pump inhibitors improves asthma control.

Objective: To determine whether lansoprazole is effective in reducing asthma symptoms in children without overt GER.

Design, setting, and participants: The Study of Acid Reflux in Children With Asthma, a randomized, masked, placebo-controlled, parallel clinical trial that compared lansoprazole with placebo in children with poor asthma control who were receiving inhaled corticosteroid treatment. Three hundred six participants enrolled from April 2007 to September 2010 at 19 US academic clinical centers were followed up for 24 weeks. A subgroup had an esophageal pH study before randomization.

Intervention: Participating children were randomly assigned to receive either lansoprazole, 15 mg/d if weighing less than 30 kg or 30 mg/d if weighing 30 kg or more (n = 149), or placebo (n = 157).

Main outcome measures: The primary outcome measure was change in Asthma Control Questionnaire (ACQ) score (range, 0-6; a 0.5-unit change is considered clinically meaningful). Secondary outcome measures included lung function measures, asthma-related quality of life, and episodes of poor asthma control.

Results: The mean age was 11 years (SD, 3 years). The mean difference in change (lansoprazole minus placebo) in the ACQ score was 0.2 units (95% CI, 0.0-0.3 units). There were no statistically significant differences in the mean difference in change for the secondary outcomes of forced expiratory volume in the first second (0.0 L; 95% CI, -0.1 to 0.1 L), asthma-related quality of life (-0.1; 95% CI, -0.3 to 0.1), or rate of episodes of poor asthma control (relative risk, 1.2; 95% CI, 0.9-1.5). Among the 115 children with esophageal pH studies, the prevalence of GER was 43%. In the subgroup with a positive pH study, no treatment effect for lansoprazole vs placebo was observed for any asthma outcome. Children treated with lansoprazole reported more respiratory infections (relative risk, 1.3 [95% CI, 1.1-1.6]).

Conclusion: In this trial of children with poorly controlled asthma without symptoms of GER who were using inhaled corticosteroids, the addition of lansoprazole, compared with placebo, improved neither symptoms nor lung function but was associated with increased adverse events.

Trial registration: clinicaltrials.gov Identifier: NCT00442013.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CONSORT Diagram
Figure 2
Figure 2
Change in asthma control score in children with poor asthma control treated with lansoprazole and placebo.
See this image and copyright information in PMC

Comment in

References

    1. Tucci F, Resti M, Fontana R, Novembre E, Lami CA, Vierucci A. Gastroesophageal reflux and bronchial asthma: prevalence and effect of cisapride therapy. J Pediatr Gastroenterol Nutr. 1993 Oct;17(3):265–70. - PubMed
    1. Cinquetti M, Micelli S, Voltolina C, Zoppi G. The pattern of gastroesophageal reflux in asthmatic children. J Asthma. 2002 Apr;39(2):135–42. - PubMed
    1. Vandenplas Y, Rudolph CD, Di Lorenzo C, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr. 2009 Oct;49(4):498–547. - PubMed
    1. Hancox RJ, Poulton R, Taylor DR, et al. Associations between respiratory symptoms, lung function and gastrooesophageal reflux symptoms in a population-based birth cohort. Respir Res. 2006 Dec 5;7:142. - PMC - PubMed
    1. Andze GO, Brandt ML, St Vil D, Bensoussan AL, Blanchard H. Diagnosis and treatment of gastroesophageal reflux in 500 children with respiratory symptoms: The value of pH monitoring. J Pediatr Surg. 1991 Mar;26(3):295–9. - PubMed

Publication types

MeSH terms

Associated data